• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Establishment of personalized medicine through analysis of organoid derived from castration-resistant prostate cancer.

Research Project

Project/Area Number 18K09134
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56030:Urology-related
Research InstitutionHiroshima University

Principal Investigator

TEISHIMA JUN  広島大学, 医系科学研究科(医), 准教授 (20397962)

Co-Investigator(Kenkyū-buntansha) 松原 昭郎  広島大学, 医系科学研究科(医), 専門研究員 (10239064)
坂本 直也  国立研究開発法人国立がん研究センター, 国立がん研究センター・先端医療開発センター, ユニット長 (20571798)
安井 弥  広島大学, 医系科学研究科(医), 教授 (40191118)
林 哲太郎  広島大学, 医系科学研究科(医), 講師 (60612835)
神明 俊輔  広島大学, 病院(医), 助教 (70749936)
井上 省吾  広島大学, 病院(医), 講師 (90457177)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords前立腺癌 / 去勢抵抗性前立腺癌 / オルガノイド / 薬剤感受性 / 泌尿器癌 / 薬剤耐性
Outline of Final Research Achievements

Organoids were established from tissues of the normal prostate, localized prostate cancer, and CRPC. Using these organoids and prostate cancer cell lines, mechanisms through T-UCR and various molecules including KIFC1, MAPT, TUBB3, BUB1B, and procadherin B9. Evidences from these analyses were investigated and comfirmed in other urological malignant diseases.

Academic Significance and Societal Importance of the Research Achievements

オルガノイドはその由来となるヒト検体の組織学的な特徴を忠実に反映しうるモデルであり、症例の薬剤感受性評価に適している。本研究によって、多くの分子を介したCRPCに対する薬剤耐性機構について解明された。オルガノイドによる薬剤感受性のスクリーニングのデータは実臨床での薬剤の効果予測因子として有用なだけでなく、症例ごとに最適な薬剤選択を行う個別化治療を可能にする上で重要な情報となりうる。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (26 results)

All 2021 2020 2019 2018

All Journal Article (16 results) (of which Peer Reviewed: 16 results,  Open Access: 15 results) Presentation (10 results) (of which Int'l Joint Research: 2 results)

  • [Journal Article] TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer.2021

    • Author(s)
      Sekino Y, Han X, Babasaki T, Miyamoto S, Kobatake K, Kitano H, Ikeda K, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Takeshima Y, Yasui W, Matsubara A.
    • Journal Title

      Urol Oncol

      Volume: 24 Issue: 6 Pages: 112-115

    • DOI

      10.1016/j.urolonc.2021.03.001

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.2021

    • Author(s)
      Sekino Y, Han X, Kobayashi G, Babasaki T, Miyamoto S, Kobatake K, Kitano H, Ikeda K, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A
    • Journal Title

      Oncology

      Volume: - Issue: 4 Pages: 240-250

    • DOI

      10.1159/000512446

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma2020

    • Author(s)
      Sekino Yohei、Han Xiangrui、Babasaki Takashi、Miyamoto Shunsuke、Kitano Hiroyuki、Kobayashi Go、Goto Keisuke、Inoue Shogo、Hayashi Tetsutaro、Teishima Jun、Sakamoto Naoya、Sentani Kazuhiro、Oue Naohide、Yasui Wataru、Matsubara Akio
    • Journal Title

      Oncology

      Volume: 98 Issue: 10 Pages: 689-698

    • DOI

      10.1159/000506775

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer2020

    • Author(s)
      Sekino Yohei、Han Xiangrui、Babasaki Takashi、Goto Keisuke、Inoue Shogo、Hayashi Tetsutaro、Teishima Jun、Shiota Masaki、Takeshima Yukio、Yasui Wataru、Matsubara Akio
    • Journal Title

      Urologic Oncology: Seminars and Original Investigations

      Volume: 38 Issue: 10 Pages: 1-8

    • DOI

      10.1016/j.urolonc.2020.04.032

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma.2020

    • Author(s)
      Han X, Sekino Y, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A.
    • Journal Title

      Urol Oncol.

      Volume: - Issue: 6 Pages: 9-17

    • DOI

      10.1016/j.urolonc.2020.02.010

    • Related Report
      2020 Annual Research Report 2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3.2020

    • Author(s)
      Teishima J, Hayashi T, Kitano H, Sadahide K, Sekino Y, Goto K, Inoue S, Honda Y, Sentani K, Awai K, Yasui W, Matsubara A.
    • Journal Title

      Jpn J Clin Oncol.

      Volume: 50(4) Issue: 4 Pages: 473-478

    • DOI

      10.1093/jjco/hyz154

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.2020

    • Author(s)
      Kobayashi G, Sentani K, Babasaki T, Sekino Y, Shigematsu Y, Hayashi T, Oue N, Teishima J, Matsubara A, Sasaki N, Yasui W.
    • Journal Title

      Cancer Sci.

      Volume: 111(3) Issue: 3 Pages: 1020-1027

    • DOI

      10.1111/cas.14299

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.2020

    • Author(s)
      Fukuoka K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K, Shigeta M, Kobayashi K, Kajiwara M, Kadonishi Y, Tacho T, Matsubara A.
    • Journal Title

      Int Urol Nephrol.

      Volume: 52(1) Issue: 1 Pages: 77-85

    • DOI

      10.1007/s11255-019-02281-4

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.2019

    • Author(s)
      Sekino Y, Han X, Kawaguchi T, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Yasui W, Matsubara A.
    • Journal Title

      Int J Mol Sci.

      Volume: 20(16) Issue: 16 Pages: 3936-3936

    • DOI

      10.3390/ijms20163936

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma.2019

    • Author(s)
      Teishima J, Murata D, Hasegawa Y, Moriyama H, Mita K, Matsubara A.
    • Journal Title

      Int J Urol.

      Volume: 26(11) Issue: 11 Pages: 1076-1077

    • DOI

      10.1111/iju.14084

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma2019

    • Author(s)
      Sekino Yohei、Sakamoto Naoya、Sentani Kazuhiro、Oue Naohide、Teishima Jun、Matsubara Akio、Yasui Wataru
    • Journal Title

      Oncology

      Volume: 97 Issue: 3 Pages: 164-172

    • DOI

      10.1159/000500605

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] SEC11A Expression Is Associated with Basal-Like Bladder Cancer and Predicts Patient Survival2019

    • Author(s)
      Shigematsu Yoshinori、Oue Naohide、Sekino Yohei、Sakamoto Naoya、Sentani Kazuhiro、Uraoka Naohiro、Hayashi Tetsutaro、Teishima Jun、Matsubara Akio、Yasui Wataru
    • Journal Title

      Pathobiology

      Volume: 86 Issue: 4 Pages: 208-216

    • DOI

      10.1159/000497206

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.2019

    • Author(s)
      Sekino Y, Sakamoto N, Ishikawa A, Honma R, Shigematsu Y, Hayashi T, Sentani K, Oue N, Teishima J, Matsubara A, Yasui W.
    • Journal Title

      Oncol Rep.

      Volume: 41 Pages: 3111-3118

    • DOI

      10.3892/or.2019.7039

    • Related Report
      2019 Research-status Report 2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer.2019

    • Author(s)
      Sekino Y, Oue N, Koike Y, Shigematsu Y, Sakamoto N, Sentani K, Teishima J, Shiota M, Matsubara A, Yasui W.
    • Journal Title

      J Clin Med.

      Volume: 8 Issue: 2 Pages: 225-225

    • DOI

      10.3390/jcm8020225

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.2019

    • Author(s)
      Sekino Y, Oue N, Mukai S, Shigematsu Y, Goto K, Sakamoto N, Sentani K, Hayashi T, Teishima J, Matsubara A, Yasui W.
    • Journal Title

      Prostate

      Volume: 79 Issue: 2 Pages: 234-242

    • DOI

      10.1002/pros.23728

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Fibroblast Growth Factor Family in the Progression of Prostate Cancer.2019

    • Author(s)
      Teishima J, Hayashi T, Nagamatsu H, Shoji K, Shikuma H, Yamanaka R, Sekino Y, Goto K, Inoue S, Matsubara A.
    • Journal Title

      J Clin Med

      Volume: 8(2) Issue: 2 Pages: 183-183

    • DOI

      10.3390/jcm8020183

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Presentation] HMGB1 の高発現は前立腺癌の予後不良と関連する2019

    • Author(s)
      後藤 景介、関野 陽平、林 哲太郎、亭島 淳、安井 弥、松原 昭郎
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Research-status Report
  • [Presentation] 傍前立腺脂肪長は MRI/超音波融合画像標的生検で検出される前立腺 癌の予測因子である2019

    • Author(s)
      藤井 慎介、林 哲太郎、後藤 景介、関野 陽平、亭島 淳、仙谷 和弘、安井 弥、松原 昭郎
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Research-status Report
  • [Presentation] 前立腺癌における claspin の臨床病理学的分析2019

    • Author(s)
      馬場崎 隆志、仙谷 和弘、小林 剛、関野 陽平、浦岡 直礼、坂本 直也、塩田 真己、大上 直秀、亭島 淳、松原 昭郎、安井 弥
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Research-status Report
  • [Presentation] 前立腺癌におけるTUBB3のカバジタキル耐性機構への関与およびPI3K阻害薬の可能性2019

    • Author(s)
      関野陽平、韓向鋭、上野剛志、井上省吾、林哲太郎、亭島淳、塩田真己、安井弥、松原昭郎
    • Organizer
      日本泌尿器腫瘍学会第5回学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] オルガノイドを用いた前立腺研究2019

    • Author(s)
      関野陽平、後藤景介、井上省吾、林哲太郎、亭島淳、坂本直也、仙谷和弘、大上直秀、安井弥、松原昭郎
    • Organizer
      第35回前立線シンポジウム
    • Related Report
      2019 Research-status Report
  • [Presentation] ホルモン療法を行った前立腺癌における診療時転移巣数と予後の関連2019

    • Author(s)
      福岡憲一郎、後藤景介、井上省吾、林哲太郎、亭島淳、松原昭郎、三田耕司、小林加直、繁田正信、永松弘孝、角西雄一、田丁貴俊、梶原充、加藤昌生
    • Organizer
      第35回前立線シンポジウム
    • Related Report
      2019 Research-status Report
  • [Presentation] KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer.2019

    • Author(s)
      Sekino Y, Koike Y, Sakamoto N, Shiota M, Shigematsu Y, Sentani K, Oue N, Teishima J, Yasui W, Matsubara A
    • Organizer
      34th Annual EAU Congress
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.2019

    • Author(s)
      Sekino Y, Goto K, Sakamoto N, Oue N, Sentani K, Hayashi T, Teishima J, Yasui W, Matsubara A.
    • Organizer
      34th Annual EAU Congress
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer.2018

    • Author(s)
      Sekino Y, Koike Y, Shigematsu Y, Hattori T, Sakamoto N, Shiota M, Sentani K, Oue N, Teishima J, Matsubara A, Yasui W
    • Organizer
      第77回日本癌学会総会
    • Related Report
      2018 Research-status Report
  • [Presentation] Significance of endocrine fibroblast growth factor subfamily as serum biomarkers in castration-resistant prostate cancer.2018

    • Author(s)
      Teishima J, Yamaguchi Y, Nagamatsu H, Shikuma H, Fujii S, Goto K, Shinmei S, Inoue S, Hayashi T, Matsubara A.
    • Organizer
      第77回日本癌学会総会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi